Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Relaxin Therapy for Atrial Fibrillation

NCT07359872 is registered in ClinicalTrials.gov with Deeptankar DeMazumder as lead sponsor.

NCT NCT07359872
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07359872 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Relaxin Therapy for Atrial Fibrillation
Lead sponsor
Deeptankar DeMazumder
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
January 1, 2027
Completion date
December 31, 2030
Enrollment
208 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ablation of atrial fibrillation, arrhythmia, atrial fibrillation (af), catheter ablation, heart failure, major cardiovascular event, oxidative stress, stroke